Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Bioburden

Container closure integrity, and the tests that actually probe it

A sterile product is sterile only for as long as its container closure system excludes the outside world. Integrity is testable, and the tests are cheap by the standards of this trade.

Particulate matter is the quality attribute a buyer can partly assess without any instrument at all. Visible inspection against light and dark backgrounds, performed properly, detects particles down to roughly the fifty micron range, and every regulated injectable batch is inspected that way, container by container. Subvisible particles are counted instrumentally, most often by light obscuration, and the compendial limits for a small-volume injection are six thousand particles of ten microns or greater and six hundred of twenty-five microns or greater per container. Those are ceilings for release, not descriptions of a good product.

Container closure integrity, method by method

The compendial guidance divides leak test methods into probabilistic and deterministic families and is explicit about preferring the second. Probabilistic methods — dye ingress under vacuum, microbial immersion challenge, bubble emission — rely on a sequence of stochastic events, and their sensitivity is poor and hard to quantify. A dye ingress test can pass a container with a defect large enough to admit an organism, because the dye happened not to travel.

Deterministic methods measure a physical quantity with a continuous response. Vacuum decay monitors pressure rise in an evacuated test chamber. High-voltage leak detection measures current through the container wall and is well suited to liquid-filled units. Laser-based headspace analysis interrogates the gas inside a sealed container non-destructively, which permits repeated measurement of the same unit across a stability programme. Helium mass spectrometry resolves the smallest defects of any method in routine use.

The threshold that matters is the maximum allowable leakage limit — the defect size below which microbial ingress does not occur under the conditions the product will see. Establishing it for a given package is a piece of work, and once established it converts an argument about seals into a measurement.1

Fourth puncture, fifth puncture: the elastomer as a physical object

A multiple-dose closure is engineered to reseal after a defined number of penetrations by a needle of defined gauge, and the qualification data behind that claim is generated with a specific needle geometry at a specific rate. Beyond that number, the resealing behaviour is not characterised, and the failure is not usually dramatic: the elastomer simply stops closing fully behind the needle track.

Two related phenomena deserve naming. Coring is the removal of a fragment of elastomer by the needle tip, which both leaves a particle in the solution and creates a channel that does not reseal. It is more likely with larger-gauge needles, with repeated penetration through the same point, and with a needle that has already been used and blunted. Fragmentation testing is a compendial requirement for elastomeric closures precisely because of it.

The practical inference available to a reader is not a recommendation, because this publication does not make those. It is an observation about the object: a closure has a puncture budget, that budget is a number somebody determined experimentally, nobody in this trade publishes it, and the elastomer behaves according to the number rather than according to what anybody assumed. Rotating the entry point and using a fresh needle each time are answers to a mechanical problem, not to a microbiological one.

Twenty containers, fourteen days, destroyed. That is the entire empirical basis of the finished-product sterility claim.

On the compendial sterility test

Particulate matter, visible and subvisible

Injectable products are required to be essentially free of visible particulates, and every container in a regulated batch is inspected against dark and light backgrounds under defined illumination. The detection threshold for a trained inspector is somewhere near fifty microns for a contrasting particle, and the inspection is a hundred per cent operation rather than a sample-based one, which makes it unusual among quality tests.

Subvisible particles are counted instrumentally. Light obscuration is the primary compendial method, with microscopic membrane counting as the alternative when the sample defeats it. For a small-volume injection the limits are six thousand particles at or above ten microns and six hundred at or above twenty-five microns per container. Products that are themselves proteinaceous get a distinct chapter, because inherent aggregates complicate the counting and the method has to distinguish them from extrinsic contamination.

For a private buyer, visible inspection is the one quality operation available without instrumentation, and it is worth doing carefully: a lyophilised cake that has collapsed to a glassy disc, a reconstituted solution showing a faint tyndall haze on rotation, a fibre against a dark card. None of those is a sterility finding. All of them are evidence about how the product was made and how it has travelled.23

Bacterial endotoxin determination, twelve vials, nine suppliers
VialLabelResult (EU/vial)EU per mg peptideAgainst 350 EU/h allowance
15 mg<0.5<0.10Below quantitation
25 mg1.20.240.3%
310 mg2.80.280.8%
45 mg<0.5<0.10Below quantitation
55 mg14.62.924.2%
610 mg3.10.310.9%
715 mg6.40.431.8%
85 mg38.27.6410.9%
95 mg0.90.180.3%
1010 mg4.70.471.3%
115 mg<0.5<0.10Below quantitation
125 mg112.022.4032.0%
Single determinations by kinetic chromogenic assay at one accredited contract laboratory; method suitability established for each matrix; results expressed per vial as received and per mg of labelled nominal mass. The final column expresses the whole vial against the hourly allowance for a 70 kg subject and is arithmetic, not a safety assessment. Twelve vials from nine suppliers is not a survey.

What the cake tells you

A lyophilised plug is a physical record of the cycle that produced it. A well-formed cake occupies close to the volume of the solution that was frozen, has a matte, uniform appearance, retains a defined edge where it met the glass, and dissolves rapidly and completely on addition of diluent. That appearance indicates that the product was frozen below its critical formulation temperature and dried without the structure collapsing.

Departures are informative. A shrunken, translucent or glassy plug suggests collapse during primary drying — the ice sublimed faster than the amorphous matrix could hold its structure — which is associated with higher residual moisture and a shorter shelf life. A cake that has partly detached and moves freely suggests mechanical handling after drying, which is cosmetic. A cake showing melt-back at the base, or a visible meniscus line, suggests a shelf temperature excursion. Slow or incomplete reconstitution suggests either collapse or an unfavourable surface.

None of these observations is a purity finding, a sterility finding or an endotoxin finding, and it is important not to overclaim. What they are is the only direct evidence about process control that arrives in the box, and reading them costs nothing. The Journal photographs every cake it receives before opening the vial, for exactly that reason.4

A note on method and sourcing

The compendial material in this article is drawn from the current general chapters of the United States Pharmacopeia and the European Pharmacopoeia, read in the original rather than in summary, and from the international standards on aseptic processing and on laboratory competence. Where a chapter has changed status recently — as the recombinant reagent chapters have — we say so, because a reader consulting an older edition will find a different framing.

Where the Journal reports a number it obtained itself, it states the laboratory’s accreditation status, the method family, whether method suitability was established, and the number of determinations. Where we report what a company told us, we distinguish an answer from a refusal and a refusal from a non-response, because those three things are routinely collapsed in coverage of this trade and they are not the same.

Corrections to this department are handled by the standards desk, which reads every letter and records the outcome in the log. Readers who believe a paragraph here overstates its evidence are asked to write to standards@compoundjournal.com; readers with documents to send, including certificates they would like read, should write to letters@compoundjournal.com. We do not publish correspondents’ names without permission and we do not identify the source of a certificate.

The Journal’s conclusion on this subject has not changed since the first time we put the questions. A purity certificate is a good document that is being asked to do a job it was never designed for, and the fix is additive rather than adversarial: five lines, four of which are allowed to say that a test was not performed. Every company we wrote to could add them this quarter without a change to a single process.

References

  1. United States Pharmacopeia. General Chapter ⟨1207⟩ Package Integrity Evaluation — Sterile Products. USP–NF, Rockville, MD.
  2. United States Pharmacopeia. General Chapter ⟨788⟩ Particulate Matter in Injections. USP–NF, Rockville, MD.
  3. United States Pharmacopeia. General Chapter ⟨787⟩ Subvisible Particulate Matter in Therapeutic Protein Injections. USP–NF, Rockville, MD.
  4. “Cake appearance, collapse temperature and residual moisture in lyophilised peptide formulations.” AAPS PharmSciTech. 2019;20(7):286.

Related coverage